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Abstract
Objective—The aim was to evaluate the therapeutic potential of human skeletal muscle-derived
myoendothelial cells for myocardial infarct repair.
Background—We have recently identified and purified a novel population of myoendothelial cells
from human skeletal muscle. These cells co-express myogenic and endothelial cell markers and
produce robust muscle regeneration when injected into cardiotoxin-injured skeletal muscle.
Methods—Myoendothelial cells were isolated from biopsies of human skeletal muscle using a
fluorescence-activated cell sorter along with populations of regular myoblasts and endothelial cells.
Acute myocardial infarction was induced in male immune-deficient mice, and cells were directly
injected into the ischemic area. Cardiac function was assessed by echocardiography, and donor cell
engraftment, angiogenesis, scar tissue, endogenous cardiomyocyte proliferation and apoptosis were
all evaluated by immunohistochemistry.
Results—A greater improvement in left ventricular function was observed after intramyocardial
injection of myoendothelial cells when compared to hearts injected with myoblast or endothelial
cells. Transplanted myoendothelial cells generated robust engraftments within the infarcted
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myocardium, and also stimulated angiogenesis, attenuation of scar tissue and proliferation and
survival of endogenous cardiomyocytes more effectively than transplanted myoblasts or endothelial
cells.
Conclusions—Our findings suggest that myoendothelial cells represent a novel cell population
from human skeletal muscle that may hold promise for cardiac repair.
Keywords
Human Stem Cells; Myocardial Infarction; Paracrine factors; Skeletal muscle; VEGF
Introduction
The number of patients suffering from severe heart failure after myocardial infarction is
increasing in Western countries. As an alternative to heart transplantation, cellular
cardiomyoplasty is a promising new approach for preventing advanced heart failure and
restoring cardiac function in injured hearts. Researchers have investigated a variety of cell
sources for cardiac repair (1-6). Initial studies in cell therapy for cardiac repair used committed
skeletal myoblasts (SkMs), largely because they can be readily harvested and easily expanded
in vitro prior to autologous transplantation. However, high cell-death rates were reported
shortly after SkMs injection in both cardiac and skeletal muscles (7-11), which has hindered
the therapeutic usefulness of SkMs. Many subsequent attempts have been made to identify and
isolate alternative stem cells or progenitors from skeletal muscle that could have a greater
capacity for post-transplantation cell survival and muscle regeneration (12).
We have previously isolated a population of skeletal muscle-derived stem cells (MDSCs) that
adhere much slower to culture flasks than committed SkMs following enzymatic dissociation
of murine skeletal muscle (13). When injected into the myocardium of infarcted hearts, MDSCs
displayed excellent survival and engraftment, induced angiogenesis, and improved left
ventricular function in a more effective manner when compared to the transplantation of SkMs
(14). This distinct difference between mouse SkMs and MDSCs for MI repair indicated that
skeletal muscle-derived progenitor cells are heterogeneous in therapeutic efficacy.
Although murine MDSCs display many characteristics associated with the myogenic lineage,
these cells also have attributes typically associated with the endothelial lineage. Upon isolation,
MDSCs expressed CD34, a marker characteristic of endothelial progenitor cells. In addition,
these cells differentiated into endothelial cells and promoted angiogenesis either upon
stimulation with vascular endothelial growth factor (VEGF) in culture or after transplantation
into skeletal and cardiac muscles (13-15). Studies published by other investigators have
documented the presence of myogenic progenitor cells that coexpress markers associated with
the myogenic and endothelial lineages in the interstitial spaces of adult mouse skeletal muscle
and in the dorsal aorta of mouse embryos (16,17). Together, these findings led us to the recent
identification and isolation of progenitor cells residing within adult human skeletal muscle that
also coexpress myogenic and endothelial cell markers (18). Transplantation of these
myoendothelial cells into the injured skeletal muscles of immunodeficient mice resulted in
considerably more de novo myofibers when compared to the injection of conventional
myogenic and endothelial cells (18).
Here, we investigated the therapeutic potential of myoendothelial cells for cardiac repair using
an acute myocardial infarction model created in immunodeficient mice. We show that
myoendothelial cells provided greater therapeutic benefit after myocardial infarction than did
endothelial cells, myogenic cells, and unsorted myoblasts. This therapeutic advantage may be
collectively attributed to the high regenerative, angiogenic, anti-fibrotic, and cardio-protective
and -stimulatory effects of myoendothelial cells.
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Methods
Human Skeletal Muscle Cell Isolation
The procurement of human skeletal muscle biopsies (male, 21 and 23 yrs old, female, 26 yrs
old) from The National Disease Research Interchange was approved by the Institutional
Review Board at the University of Pittsburgh Medical Center. The human skeletal muscle
biopsies were placed in solution with Hank's balanced salt solution (HBSS) and were
transported to the laboratory on ice.
The human skeletal muscle biopsy was finely minced, and then digested for 60 minutes at 37°
C with type I and type IV collagenase (100 u/mL) and dispase (1.2 u/mL; all from GIBCO,
Invitrogen Corporation, Carlsbad, CA). The digested tissue was pelleted and resuspended in
Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) and 1% penicillin/streptomycin (P/S). The pellet was then enzymatically dissociated,
and passed through a 40-μm filter to obtain a single- cell suspension. Approximately 7×105
cells were recovered per gram of tissue.
We used fluorescence-activated cell sorting (FACS) to isolate various cell fractions based on
their expression of the cell surface markers CD56, CD34, and CD144, as previously described
(18). We also used an unpurified (unsorted) cell population as a control. Briefly, the cell pellet
was suspended in DMEM that was supplemented with 2% FBS. The cell solution was then
incubated on ice with APC-Cy7-conjugated mouse anti-human CD45, APC-conjugated mouse
anti-human CD34, PE-Cy7-conjugated mouse anti-human CD56 (all from BD Biosciences,
San Jose, CA), and PE-conjugated mouse anti-human CD144 (Beckman Coulter, Fullerton,
CA). Isotype control antibodies were APC-Cy7-, APC-, PE-Cy7- and PE-conjugated mouse
IgG1 (all from BD Biosciences, San Jose, CA). 7-amino-actinomycin D (7-AAD, ViaProbe;
BD Pharmingen, San Jose, CA) was added to each tube for dead cell exclusion. Background
staining was evaluated with isotype-matched control antibodies and a CompBeads set (Becton-
Dickinson, San Jose, CA) was used to optimize fluorescence compensation settings for multi-
color analyses and sorts. A minimum of 1×105 live cell events were analyzed using a
FACSCalibur flow-cytometer (Becton-Dickinson, San Jose, CA) and the CellQuest™ software
(Becton-Dickinson). Cell sorting was performed on a FACSAria™ dual-laser fluorescence cell
sorter (Becton-Dickinson, San Jose, CA). Sorted cells were re-analyzed in all experiments. For
this study, we collected the following populations: CD56+CD34-CD144-,
CD56-CD34+CD144+, and CD56+CD34+CD144+. The 3 sorted cell populations were plated
in collagen-coated 96-well plates at a density of 500 cells per well in proliferation medium
consisting of DMEM, 10% (v/v) FBS, 10% (v/v) horse serum, 1% (v/v) penicillin/
streptomycin, 1% (v/v) chick embryo extract (GIBCO-BRL, Carlsbad, CA) and incubated at
37°C in a 5% CO2 atmosphere. At 70% confluence, cells were passage dissociated with trypsin/
EDTA (GIBCO-BRL, Carlsbad, CA), replated at a cell density of 1.0-2.5×103/cm2 cells and
cultured for 3 to 4 weeks prior to intracardiac transplantation.
To track donor cell fate after injection, we transduced myoendothelial cells with a retrovirus
encoding for a nuclear LacZ (nLacZ) reporter gene as previously described (15,18).
Intramyocardial Cell Transplantation into an Acute MI
The Institutional Animal Care and Use Committee, Children's Hospital of Pittsburgh, approved
the animal and surgical procedures performed in this study (Protocol 37/04). A total of 74 male
NOD/SCID mice (The Jackson Laboratory, Bar Harbor, ME, USA) were used for this study.
Overall, 5 animals died during surgery, resulting in a 6.8% operative mortality. One animal
was excluded from this study due to the presence of a thymic lymphoma, which is known to
naturally occur on occasion in this mouse strain (19). Infarcted mice were randomly allocated
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between the types of treatment (saline, CD56+CD34-CD144-, CD56-CD34+CD144+, and
CD56+CD34+CD144+ cells) for each donor. The 3 sorted cell populations and unsorted cells
were injected (3×105 cells in solution of 30 μL of PBS per heart) into the hearts of mice
immediately after inducing myocardial infarction as previously described (14). In control mice,
30 μL of phosphate buffered saline (PBS) alone was injected. The investigator creating the
infarction injury and injecting the cells was blinded to the contents of the injectant. Histological
and functional studies were performed at 5 days and 2 and 6 weeks post-transplantation (N=14
animals sacrificed at 5 days, 25 animals sacrificed at 2 weeks, and 29 animals sacrificed at 6
weeks). Echocardiography was performed by a blinded investigator to assess the heart function
of anesthetized mice, as previously described (14).
Histological analysis
The mice were sacrificed at 5 days, 2 weeks and 6 weeks after cell transplantation for
histological evaluation of the heart tissue. Hearts were flash frozen in 2-methylbutane (Sigma)
that was pre-cooled in liquid nitrogen. For immunohistochemical assays, some excised hearts
were fixed in 10% formalin by perfusion from the ascending aorta and embedded in paraffin.
To detect proliferating human cells, cryosections were incubated with human anti-human
proliferating cell nuclei antigen (1:400, PCNA, US Biological, Swampscott, MA), at room
temperature for 2 hrs followed by the addition of goat anti-human IgG 555 (1:800, Molecular
Probes, Eugene, OR). Then, the sections were co-stained for fskMyHC as described previously
(14,15). Sections containing the highest number of fibers expressing fskMyHC were used, for
each group, to determine a regeneration index, defined as the number of fskMyHC-positive
fibers per section (14,15).
For immunofluorescent human VEGF staining, cryosections were incubated with Xgal
substrate for 2 hours and incubated overnight at 4°C with a goat anti-human VEGF (1:100,
R&D systems, Minneapolis, MN), followed by incubation with a donkey anti-goat IgG 555
(1:200, Molecular Probes, Eugene, OR).
To determine whether donor cells expressed cardiac cell markers, tissue samples were
incubated with Xgal substrate for 2 hours. Then the sections were incubated with mouse anti-
human cardiac troponin T (1:50, Abcam, Cambridge, MA), followed by donkey-anti-mouse
IgG 488 (1:400, Molecular Probes, Eugene, OR). Alternatively, Xgal-stained slides were
incubated with anti-cardiac troponin I at room temperature for 2 hrs followed by the addition
of donkey anti-goat IgG 555 (1:200, Molecular Probes, Eugene, OR).
To determine capillary density within the infarct zone, we performed immunostaining of CD31
on cryosections and measured capillary density within the infarct region of each heart, as
previously described (14).
For Ki-67 immunohistochemical staining, deparaffinized sections were immersed in preheated
sodium citrate buffer and were incubated overnight at 4°C with a rat monoclonal anti-mouse
Ki-67 antibody (1:50, DAKO, Carpinteria, CA) that does not cross-react with human Ki-67.
Positive reactivity was determined with Vectastain® Elite ABC Kit (Vector Laboratories,
Burlingame, CA) and visualized as purple with the VIP (violet-colored precipitate) substrate
kit (Vector Laboratories). To determine the number of proliferating myocytes, tissues were
counterstained with anti-cardiac troponin I (cTnI, 1:20,000, Scripps, San Diego, CA),
processed with Vectastain® Elite ABC Kit (Vector), and then visualized as brown through the
DAB (3,3′- diaminobenzidine) substrate kit (Vector). The number of mitotically active
endogenous cardiomyocytes within the peri-infarct region was measured in 8 high power fields
(HPF, 400× magnification).
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For TUNEL staining, the deparaffinized sections were digested with proteinase K following
the protocols provided by manufacturer (ApopTag® Plus Peroxidase In Situ Apoptosis
Detection Kit; Chemicon, Temecula, CA). The TUNEL stain was visualized with a substrate
system that stained purple (VIP substrate kit; Vector Laboratories, Burlingame, CA). The
samples were also lightly counterstained with anti-cardiac troponin I as described above with
the Ki-67 stain. The number of apoptotic endogenous cardiomyocytes within the peri-infarct
region was measured in 4 HPF (400× magnification) (20).
For human specific VEGF immunohistochemical staining, deparaffinzed sections were
immersed in preheated sodium citrate buffer and were incubated overnight at 4°C with a goat
anti-human VEGF (1:50, R&D systems, Minneapolis, MN). The slides were then processed
with Vectastain® Elite ABC Kit (Vector). A positive stain was visualized as brown using the
DAB substrate kit (Vector). These sections were counterstained with eosin.
We used Masson's trichrome staining kit (San Marcos, CA) to stain collagen deposition on
frozen cryosections of the heart. The area of infarct scar and the area of the entire cardiac
muscle section were measured using a digital image analyzer (Image J). Scar area fraction was
calculated as the ratio of scar area to the entire cardiac muscle area and was averaged from 7
sections per heart.
Hypoxia assay
We cultured all three cell populations under hypoxic conditions (2.5% O2) in vitro and
measured the amount of VEGF that was secreted into the cell culture supernatant by ELISA
(R&D Systems, Minneapolis, MN), as previously described (21). Total RNA (n=3) was
extracted from cell lysates using an RNeasy kit with DNase I digestion (Qiagen, Valencia,
CA). After RNA extraction, quantitative real-time PCR (qPCR) analysis was carried out as 10
μL reactions as described previously (22,23) using TaqMan® One-Step RT-PCR Master Mix
(Applied Biosystems Inc (ABI), Foster City, CA) and 1 μL total RNA as the template.
Sequences for target gene primers and probes (IDT) were as follows:
Human Vegf165 (NM 001033756) – forward: 5′ CATGCAGATTATGCGGATCAA 3′;
Reverse: 5′ TTTGTTGTGCTGTAGGAAGCTCAT 3′ and TaqMan® probe: 5′
CCTCACCAAGGCCAGCACATAGGAGA 3′;
Human Igf-I (X57025): forward-5′TGTATTGCGCACCCCTCAA3′;
Reverse: 5′TGCGTTCTTCAAATGTACTTCCTT3′; and TaqMan® probe: 5′
CAGCTCGCTCTGTCCGTGCCC 3′.
Human hgf - forward AGGCCATGGTGCTATACTCTTG
Reverse: TCAGCGCATGTTTTAATTGCA and TaqMan® probe:
CCCTCACACCCGCTGGGAGTA (5′ 6FAM and 3′ TAMRA-Sp)
Human b-fgf - forward: GGCGTGTACATGTGGTCTCAGA
Reverse: TTATGGCTCACTGCAACCTTGA and TaqMan® probe:
AAGTGATCAACCCTCCCACCTCAGCCT (5′ 6FAM 3′ TAMRA-Sp).
All target genes were normalized to the reference housekeeping gene 18S (ABI). Gene
expression levels were analyzed using SDS 2.2 Software (ABI) and were calculated as total
amount RNA (in arbitrary fluorescence units) compared to negative controls (normal O2) for
each time point based on the comparative ΔCT method (separate tubes)(24).
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Statistical analysis
All measured data are presented as mean ± standard error (SE). Kaplan-Meier survival curve
estimation with log-rank test was performed to compare the survival rate among experimental
groups. For the analysis of the echocardiographic data, the scar tissue area data, the endogenous
cardiomyocyte proliferation data, and the VEGF qPCR and ELISA data, we applied the two-
way analysis of variance (ANOVA) test and the Tukey multiple comparison test. The one-way
ANOVA and the Tukey post-hoc tests were performed to analyze the number of fskMyHC
expressing myocytes, capillary density data in all groups. For the endogenous cardiomyocyte
apoptosis data, we applied the Kruskal-Wallis and the Dunn's multiple comparison tests at each
time point. The Student's t-test was performed for the VEGF and HGF gene expression data
in myoendothelial cells cultured under normoxic and hypoxic culture conditions. Statistical
significance was set at P<0.05. All statistical tests were performed using SigmaStat (Systat
Software Inc, Point Richmond, CA).
Results
Cell Isolation by FACS
Cells were isolated from 3 samples of adult human skeletal muscle [(1) male, age 21 years; (2)
male, age 23 years; (3) female, age 26 years] by FACS on the basis of their differential
expression of the myogenic (CD56) and endothelial cell (CD34 and CD144) surface markers
(18). CD45 was used to exclude hematopoietic cells (18). The fraction of myoendothelial cells
(CD56+CD34+CD144+CD45-) represented 1.8% of the total cell population, while endothelial
cells (CD56-CD34+CD144+CD45-) and myogenic cells (CD56+CD34-CD144-CD45-)
accounted for 9.0% and 2.6%, respectively. The mean numbers of viable sorted cells which
were recovered per experiment were 9.6×104 CD56+CD34-CD144-CD45- cells, 45.8×104
CD56-CD34+CD144+CD45- cells, and 8.8×104 CD56+CD34+CD144+CD45- cells. Purities of
these 3 sorted cell populations were, respectively, 89.1%, 92.8% and 81.1%, as confirmed by
flow re-analysis. The myogenic, endothelial and myoendothelial cell isolates were expanded
in culture prior to intramyocardial transplantation, using a protocol previously described (18).
We have previously evaluated the myogenic and endothelial cell phenotype of sorted cells after
cultivation using the myogenic marker CD56 and the endothelial cell markers CD146 and Ulex
europeaus agglutinin 1 receptor (UEA-1-R)(18). The phenotype of the sorted endothelial cells
(CD56-CD34+CD144+) and myoendothelial cells (CD56+CD34+CD144+) changed after
expansion in tissue culture flasks. Myogenic cells (CD56+CD34-CD144-) retained a high level
of CD56 expression but a portion of cells also expressed CD146 after cultivation. Interestingly,
65% of cultured endothelial cells expressed CD56 even though this population was 92.8% pure
(CD56-CD34+CD144+) after FACS isolation. A large portion of cultured myoendothelial cells
retained a myogenic and endothelial cell phenotype. Expression of UEA-1-R was low in all
cell types.
Cardiac Repair
The therapeutic effect of myogenic, endothelial, and myoendothelial cells for cardiac repair
was assessed in an immunodeficient mouse model of an acute myocardial infarction (MI). Over
the course of this study, we did not observe a significant difference in survival rates among the
groups (P=0.13; Kaplan-Meier Survival Curve, Figure1A). In uninjured NOD/SCID mice (age
12 weeks, weight 27.2 ± 1.4 g), we have measured baseline LV dimensions and function by
echocardiography. Baseline end-diastolic area (EDA) of uninjured mice (n=5 mice) was 9.3 ±
0.3 mm2 (Figure 1B), and baseline fractional area change (FAC) was 46.4 ± 1.5 % (n=5, Figure
1C). The hearts in all 3 cell groups had smaller left ventricular (LV) dimensions, as assessed
by end diastolic area (EDA, Figure 1B) and end systolic area (ESA, data not shown), when
compared to the control group, which consisted of phosphate-buffered saline (PBS) injections
Okada et al. Page 6
J Am Coll Cardiol. Author manuscript; available in PMC 2009 December 2.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
into the heart. Compared to baseline uninjured hearts and control PBS-injected hearts (12.2 ±
1.5 mm2), intracardiac injections of myoendothelial cells (9.6 ± 0.8 mm2) tended to preserve
LV dimensions at 2 weeks after cell transplantation. However, by 6 weeks, the LV expanded
in hearts injected with myoendothelial cells (12.6 ± 0.8 mm2), and was only slightly less than
PBS-injected hearts (13.8 ± 1.7 mm2; Figure 1B).
LV contractility, as determined by fractional area change (FAC) values, improved 20% and
17% at 2 and 6 weeks after MI, respectively, in the myogenic group (2 weeks: FAC 19.6 ±
2.9%, 6 weeks: 18.5 ± 2.4%) compared to the control PBS group (2 weeks: 16.4 ± 2.6%, 6
weeks: 15.9 ± 3.1%) (Figure 1C). Transplanted endothelial cells (2 weeks: 23.4 ± 1.4%, 6
weeks: 19.0 ± 1.9%) improved systolic function by 47% and 25% at 2 and 6 weeks,
respectively, compared to control injections of PBS (Figure 1C). In comparison to the other 2
cell groups, LV contractility was the strongest in the myoendothelial group (2 weeks: 30.0 ±
3.0%, 6 weeks: 27.8 ± 3.3%) resulting in FAC values that were 84% and 75% greater than the
control PBS group at the 2 and 6 week time points, respectively (Figure 1C; P<0.05,
myoendothelial cells versus myogenic cells and PBS).
We performed injections using unsorted human myoblasts isolated from the same donor
(Figure 1D and E). No difference in LV dimensions was observed between the unsorted
myoblasts (EDA: 11.7 ± 0.6 mm2) and sorted CD56+ myogenic cells (11.5 ± 0.5 mm2; Figure
1D). Hearts injected with unsorted human myoblasts displayed poor LV contractility (FAC:
18.3 ± 2.1%) at 2 weeks after MI, which was comparable to hearts injected with the sorted
CD56+ myogenic cell population (CD56+CD34-CD144-, FAC 19.6 ± 2.9%, Figure 1E).
Injection of all 3 sorted cell populations was repeated using cell isolates from another donor
(male, 21 years old). Again, hearts injected with myoendothelial cells (FAC: 37.4 ± 1.9%)
displayed the strongest LV contraction compared to the other groups at 2 weeks after MI
(P<0.05, myoendothelial cells vs. myogenic cells, endothelial cells, and control PBS). In
comparison to the injection of PBS only (23.0 ± 1.9%), cardiac contractility improved 62%
with the injection of myoendothelial cells, 28% with the injection of endothelial cells (28.7 ±
2.8%), and 7% with the injection of myogenic cells (24.6 ± 1.3%).
Scar Tissue Formation
The extent of scar tissue formation within the infarcted area was evaluated using Masson's
trichrome stain (Figure 2A). At both time points (2 weeks and 6 weeks), LV infarct scar area
was smaller, as determined by scar area fraction values, in all 3 cell groups when compared to
the control PBS group, with the most notable improvement occurring at the 6 week time point
(Figure 2B). Hearts injected with myoendothelial cells exhibited less scar tissue than those
injected with PBS 2 and 6 weeks after infarction (P<0.05, myoendothelial cells versus PBS,
Figure 2B).
Engraftment
Cell engraftment was assessed by immunohistochemical analysis of the skeletal muscle-
specific marker fast skeletal myosin heavy chain (fskMyHC, green, Figure 3B). The majority
of engrafted human cell-derived myocytes had aligned with the host myocardial fibers and
along the ischemic border zone and scar area (Figure 3A, B). Interestingly, the CD56+
myogenic cells regenerated less fskMyHC+ myofibers when compared to the
CD34+CD144+ endothelial cells (Figure 3C). Compared to both of these groups, the
CD56+CD34+CD144+ myoendothelial cells regenerated significantly more skeletal myofibers
(P<0.05, myoendothelial cells versus myogenic cells, endothelial cells; Figure 3C), indicating
that these cells have an efficient transplantation capacity, as observed in skeletal muscle (18).
Heart sections were also co-stained with antibodies directed against human-specific
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proliferating cell nuclear antigen (PCNA) and fskMyHC (Figure 3D). A few nuclei (blue) in
the fskMyHC engraftment region (green) expressed PCNA (red). This finding confirms the
presence of human cells within the fskMyHC+ engraftment region, and suggests that a fraction
of myoendothelial cells are proliferative for up to 2 weeks following implantation.
Evaluation of Cardiac Differentiation
In hearts injected with nLacZ-transduced myoendothelial cells, we evaluated whether any
donor cells colocalized with the cardiac-specific isoforms of troponin I (cTnI) and troponin T
(cTnT) and the gap junction protein connexin43, a protein essential for intercellular electrical
connections between cardiomyocytes (14,15).
We observed only a few cells containing nLacZ+ nuclei that colocalized with cTnI (Figure 3E-
H) and cTnT (Figure 3I-L). However, the vast majority of nLacZ+ cells did not colocalize with
these cardiac markers. In addition, we did not observe expression of connexin43 at the interface
of the graft and host myocardium, suggesting that engrafted cells were electrically isolated
from host cardiomyocytes. Connexin43 gap junction proteins were not expressed by donor
cells within the graft.
Neoangiogenesis
Capillary density within the infarct tissue was assessed by CD31 [PECAM] immunostaining
(red, Figure 4A). Intramyocardial transplantation of all 3 cell populations resulted in an increase
in the number of CD31+ capillaries when compared to the transplantation of PBS only (P<0.05,
myoendothelial cells, myogenic cells, and endothelial cells versus PBS; Figure 4B). Of the 3
cell types, the myoendothelial cells induced the greatest increase of capillaries in the infarct
area (P<0.05, myoendothelial cells versus myogenic cells and endothelial cells; Figure 4B),
which was followed by endothelial cells and myogenic cells, respectively. These findings
suggest that each transplanted cell population had an angiogenic effect; however,
myoendothelial cells were the most effective at stimulating angiogenesis.
Endogenous Cardiomyocyte Proliferation and Apoptosis
We have assessed host cardiomyocyte proliferation and apoptosis at 5 days and 6 weeks after
MI. Five days after MI, we observed numerous proliferating endogenous cells located at the
infarct border zone. We observed no difference among the groups for the total number of ki-67–
positive cells at the peri-infarct zone (myoendothelial cells 68 ± 10 ki-67+ cells, n=3 hearts;
endothelial cells 63 ± 16, n=4; myogenic cells 63 ± 12, n=3; saline control 60 ± 5, n=4;
P=0.859). We also measured the number of cells that co-expressed both ki-67 and cardiac
troponin I (cTnI) within the peri-infarct region (Figure 5A, B, and C). Five days after cell
transplantation, hearts injected with myoendothelial cells had more proliferating ki-67(+)/cTnI
(+) cardiomyocytes (13 ± 4 cardiomyocytes) within the infarct border zone than hearts injected
with either endothelial cells (3 ± 1), myogenic cells (2 ± 1), or saline (3 ± 1) (P<0.05,
myoendothelial cells versus myogenic cells, endothelial cells, and PBS; Figure 5C). Six weeks
after cell transplantation, in hearts injected with CD56+ myogenic cells (1 ± 1) and
CD34+CD144+ endothelial cells (2 ± 1), the number of proliferating endogenous cTnI+
cardiomyocytes was comparable to control hearts injected with PBS (1 ± 1) 6 weeks after MI
(Figure 5C). However, endogenous cardiomyocyte proliferation was the highest in hearts
injected with myoendothelial cells (6 ± 1) (P<0.05, myoendothelial cells versus myogenic cells,
endothelial cells, and PBS; Figure 5C).
We performed multi-label staining for DNA end-labeling by terminal dUPT nick end-labeling
(TUNEL) and cTnI to determine the effect of cell therapy on endogenous cardiomyocyte
apoptosis in the peri-infarct regions. At 5 days after MI, the occurrence of apoptotic
cardiomyocytes within the peri-infarct regions was less frequent in hearts injected with
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myoendothelial cells (7 ± 1 TUNEL+ cardiomyocytes) when compared to the transplantation
of PBS (27 ± 6), myogenic cells (20 ± 3) and endothelial cells (14 ± 2) (P<0.05, myoendothelial
cells versus PBS, Figure 5D). By six weeks after cell transplantation, the number of apoptotic
cardiomyocytes decreased considerably. Hearts injected with all 3 cell types had slightly fewer
apoptotic cardiomyocytes in the peri-infarct regions when compared to the transplantation of
PBS only (P<0.05 myoendothelial cells versus PBS, Figure 5D). Taken together, these results
suggest that the transplantation of myoendothelial cells had a beneficial effect on endogenous
cardiomyocyte proliferation and apoptosis, with the most marked effect occurring shortly after
implantation.
Analysis of Paracrine Factors
For all 3 populations, we used quantitative real-time PCR (qPCR) to measure the expression
of secretable factor genes, including vascular endothelial growth factor (Vegf), hepatocyte
growth factor (Hgf) (25-27), insulin-like growth factor-I (Igf-I), and basic fibroblast growth
factor (b-Fgf). All of these factors are known to act as therapeutic agents in the heart (28,29).
Under normal culture conditions, we observed expression of Vegf, Hgf, and Igf-I genes from
myoendothelial cells of 1st donor sample. There was no detectable expression of the b-Fgf
gene (Figure 6A). Interestingly, while the Hgf gene was expressed in CD56+CD34+CD144+
cells (myoendothelial), we did not observe measurable expression in CD56+CD34-CD144-
(myogenic) and CD56-CD34+CD144+ (endothelial) cells (data not shown). Hypoxic
conditions stimulated a 4.4-fold increase in Vegf gene expression by myoendothelial cells. In
contrast, the expression of Hgf and Igf-1 genes decreased upon exposure to hypoxia, and b-
Fgf gene expression remained undetectable (Figure 6A). Of note, Vegf gene expression was
considerably higher when compared to other analyzed factors (Figure 6A), suggesting that
VEGF may represent a major factor secreted by myoendothelial cells, as previously observed
with murine MDSCs (21). All 3 populations increased Vegf gene expression under hypoxic
conditions relative to normoxia (P<0.01, normoxia versus hypoxia, Figure 6B). The VEGF
mRNA results were further confirmed by ELISA where all tested cell types had at least a 4-
fold increase in VEGF protein secretion under hypoxic conditions when compared to control
normoxic conditions (P<0.05, normoxia versus hypoxia, Figure 6C). Although only a few
factors were analyzed here, our findings suggest that myoendothelial cells secrete factors,
especially when subjected to ischemic conditions, which may have therapeutic effect in vivo.
In Vivo VEGF Expression
We evaluated whether human VEGF was expressed in vivo. Using an antibody that is specific
for human VEGF, we observed human VEGF expression within cell-injected hearts 5 days
after MI (data not shown). Engrafted nLacZ-tranduced donor cells were found to colocalize
with human VEGF (data not shown).
Discussion
Satellite cells, which are myogenic progenitor cells located beneath the basal lamina of skeletal
myofibers, are known to reside in close proximity to capillaries (30). A developmental
relationship between satellite cells and endothelial cells, besides their spatially close proximity
in skeletal muscle, has been suggested by Tamaki and colleagues, who have documented the
presence of myogenic progenitor cells that coexpress markers associated with the myogenic
and endothelial lineages within the interstitial spaces of murine skeletal muscle (16). In
addition, the identification of skeletal muscle progenitors originating from the embryonic
dorsal aorta has led to the notion that a subset of satellite cells may have a vascular origin
(17). Our research has resulted in the identification and isolation of progenitor cells residing
within adult human skeletal muscle that coexpress myogenic and endothelial cell markers
(18). These myoendothelial cells also demonstrated a potent regenerative capacity when
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transplanted into injured skeletal muscles (18), indicating that they may yield a better
therapeutic promise than myoblasts.
The main finding in this study is that transplantation of human myoendothelial cells attenuated
LV dysfunction more effectively than either myogenic or endothelial cells in an acute MI. At
the 6 week time point, cardiac contractility in the myoendothelial cell-injected hearts was 40%
and 50% greater compared to hearts injected with either endothelial cells or myogenic cells,
respectively. The improved therapeutic benefit elicited by the injection of myoendothelial cells
could be at least partially explained by the reduced levels of scar tissue and apoptotic
cardiomyocytes and the increased levels of engraftment, angiogenesis, and endogenous
cardiomyocyte proliferation when compared to that observed with myogenic and endothelial
cells.
A key goal of cardiac cell transplantation for myocardial infarct repair is to modify LV
remodeling in order to increase functional repair. Despite the fact that all 3 cell types did not
prevent LV dilation compared to PBS controls, myoendothelial cells significantly reduced LV
infarct size and sustained LV contractile function better than the other 2 cell types and PBS. It
remains to be investigated if the beneficial effects of myoendothelial cells will reduce LV
dilation at longer time points.
Our histological analysis demonstrated a higher level of engraftment based on the number of
regenerated myofibers in myoendothelial cell-injected hearts when compared to the other cell-
injected hearts. Because there is a correlation between the magnitude of functional
improvement and donor cell engraftment (31-33), the large degree of engraftment of
myoendothelial (CD56+CD34+CD144+) cells is a good indicator of their enhanced ability to
improve cardiac function. This superior engraftment is likely related to the superior survival
characteristics of myoendothelial cells, as observed in skeletal muscle (18) which could be due
to their enhanced ability to resist oxidative stress compared to myogenic and endothelial cells.
This same enhanced survival characteristic was also observed with murine MDSCs, which
were found to be more resistant to oxidative stress than skeletal myoblasts (14).
A few of the injected myoendothelial cells were observed to express cardiac cell markers within
the infarcted heart. The frequency of this event was quite rare as the vast majority of engrafted
donor cells were negative for cTnI and cTnT. It is undetermined from these experiments
whether these cardiac marker-expressing donor cells originated from differentiation or fusion
with host cardiomyocyte (14,15) (34).
All 3 cell populations had an angiogenic effect upon transplantation, a finding that is consistent
with many reports in the field (1,14,20,35-37). Neovascularization of the infarct may help to
salvage at-risk myocardium by promoting endogenous cell survival and proliferation,
stimulating hibernating myocardium, enhancing scar viability, and attenuating adverse
remodeling (20). When we previously reported on the intramyocardial injection of MDSCs,
we observed that most of the new vasculature that formed within the infarct was of host origin.
The occurrence of transplanted murine MDSCs differentiating into blood vessels was rare
(14,15), indicating that the presence of new vasculature within the infarct may be due to
paracrine factors. Likewise, in this study, we found that only a few donor cells had incorporated
into the neovasculature, as evidenced by our use of a human-specific CD31 antibody (data not
shown), suggesting that the new capillaries are of host-origin and may be induced by paracrine
factor released by the donor cells. In a recent study, we reported that one of the most potent
angiogenic factors, VEGF, may be critical for the occurrence of angiogenesis in murine
MDSCs-treated hearts (21). Overall, the ability of myoendothelial cells to induce the greatest
level of angiogenesis within the infarct may be a major factor underlying their strong
therapeutic effect.
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Recent reports have demonstrated that a population of myocytes within the myocardium is
capable of proliferating after infarction (38,39). Schuster et al. report that myocardial
neovascularization results in regeneration and cell cycling of endogenous cardiomyocytes,
suggesting that agents that increase myocardial homing of bone marrow angioblasts could
induce endogenous cardiomyocytes to enter the cell cycle and improve functional cardiac
recovery (40). We observed that mouse cardiomyocytes located within the peri-infarct region
in animals receiving human myoendothelial cells demonstrated much higher mitotic activity
than in those receiving PBS at 5days after cell transplantation. The origin of these proliferating
cells remains unknown, but they could originate from resident cardiomyocytes, differentiating
cardiac stem cells, or from circulating stem cells that home to the myocardium after infarction
(39).
Additionally, TUNEL staining showed reduced levels of apoptosis, suggesting that
myoendothelial (CD56+CD34+CD144+) cells transplantation was effective at reducing
endogenous cardiomyocyte apoptosis at the initial phase after myocardial infarction.
Transplanted cells may have a beneficial paracrine effect in the heart by releasing growth
factors that promote angiogenesis, cell proliferation, anti-apoptosis, anti-fibrotic effects, and
cardioprotective effect (40,41). Although we only evaluated the expression of a few secretable
factors, quantitative real-time PCR analysis showed that VEGF and HGF are two factors
secreted by transplanted human muscle cells in response to the ischemic microenvironment of
the infarcted hearts. We observed elevated HGF expression in myoendothelial
(CD56+CD34+CD144+) cells but not in the other tested cell populations. It has been previously
demonstrated that HGF can greatly increase myogenic regeneration and vascularity while
reducing fibrosis inside the graft, which enhances the efficacy of SkM transplantation to
infarcted hearts (25). Out of all the factors evaluated, VEGF was the only factor to significantly
increase upon exposure to hypoxic culture conditions. Since the cells are transplanted into an
ischemic environment, VEGF may be highly secreted by the donor cells and be a major factor
in the induction of angiogenesis and promotion of endogenous cell survival (1,21,37). In
addition, VEGF and HGF may have a synergistic effect resulting in a more robust proliferative,
chemotactic, and angiogenic response than either growth factor alone (42,43).
Here, we have shown that human skeletal muscle-derived myoendothelial
(CD56+CD34+CD144+) cells represent a unique cell population with a superior ability for
myocardial infarct repair when compared to conventional myogenic or endothelial cells, as
recently observed in skeletal muscle (18). Based on the results presented here, the beneficial
therapeutic outcomes of myoendothelial cell transplantation, including the improvement of
cardiac function, attenuation of adverse cardiac remodeling, cardioprotection of at-risk
endogenous cardiac cells, and the stimulation of both infarct neovascularization and
endogenous cell proliferation, may emanate from the robust engraftment of myoendothelial
cells. In conclusion, myoendothelial cells represent a unique population of progenitor cells
from human skeletal muscle that may be similar to murine MDSCs (14) in regards to the
therapeutic repair of skeletal (18) and cardiac muscles.
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Figure 1. Survival rates and echocardiographic assessment
(A) Survival rates over 6weeks after cell transplantation in the animals injected with human
muscle derived cells or control-PBS (Kaplan-Meier Survival Curve, P=0.13). (B)
Echocardiography performed 2 and 6 weeks after cell transplantation demonstrated smaller
left ventricular (LV) areas in end-diastole of hearts injected with CD56+CD34+CD144+ cells
when compared to the other groups. (Baseline: data from NOD/SCID mice without infarction
and cellular injection.) (C) The CD56+CD34+CD144+ myoendothelial cell group also
displayed greater LV contractility, as measured by fractional area change (FAC), when
compared to the other groups at both the 2 and 6 weeks time points († P<0.05,
CD56+CD34+CD144+ cells versus CD56+CD34-CD144- cells and PBS). (D) No difference in
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LV end-diastolic areas was observed between hearts injected with unsorted myoblasts and
hearts injected with myogenic CD56+ sorted cells 2 weeks after cell transplantation. (E) The
unsorted group also displayed a similar level of LV contractility, as measured by fractional
area change (FAC), as the CD56+ cell group.
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Figure 2. Injection of myoendothelial cells reduces scar tissue formation after myocardial infarction
(A) Representative images taken from transverse sections of the left ventricle stained by
Masson's trichrome (muscle is stained red, collagen blue, nuclei black). The hearts injected
with CD56+CD34+CD144+ cells displayed smaller infarct scar areas than did the control hearts
injected with PBS only. Scale bars equal 1 mm. (B) Compared to all groups, the
CD56+CD34+CD144+ cell-injected hearts had the smallest scar tissue area 2 and 6 weeks after
infarction (* P<0.05 CD56+CD34+CD144+ cells versus PBS).
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Figure 3. Engraftment of human muscle-derived cells in the infracted heart
(A) Masson's trichrome staining (muscle is stained red, collagen blue, nuclei black) at the peri-
infarcted area of CD56+CD34+CD144+ cell-injected heart 2 weeks after cell transplantation.
Scale bar equals 500 μm. The dotted line shows the engraftment area of human muscle-derived
cells, (B) which corresponds to fast skeletal myosin heavy chain (fskMyHC)-positive (green)
immunostaining. In the image, the fskMyHC-postive myofibers are stained green, nuclei blue,
and cTnI-positive cardiomyocytes red. Only the engraftment regions expressed fskMyHC;
normal myocardium was negative for fskMyHC. Scale bar equals 50 μm. (C)
CD56+CD34+CD144+ myoendothelial cells regenerated more fskMyHC expressing myocytes
than did CD56+CD34-CD144- myogenic and CD56-CD34+CD144+ endothelial cells (*
P<0.05). (D) A few nuclei (blue) found in the fskMyHC-positive (green) engraftment area
stained positive for human-specific proliferating cell nuclear antigen (PCNA) (red, arrows).
Scale bar equals 33.3 μm. (E)-(L) Expression of a cardiac cell markers by myoendothelial cells
in vivo. (E) Engrafted myoendothelial cells expressing the nLacZ reporter gene (blue,
arrowheads) colocalized with (F) cardiac troponin I (red, arrowheads) staining. DAPI-only
(G, blue, arrow) and colocalized with troponin I (H, red and blue). (I) A nLacZ-expressing
donor cell (blue, arrowhead) colocalized with the (J) cardiac troponin T marker (green,
arrowhead). DAPI-only (K, blue, arrow) and colocalized with troponin T (L, green and blue).
Scale bars equal 50 μm.
Okada et al. Page 17
J Am Coll Cardiol. Author manuscript; available in PMC 2009 December 2.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 4. Transplanted human cells induce neoangiogenesis in the infracted heart
(A) Representative images of CD31 immunostaining in the peri-infarct and the infarct regions
of hearts transplanted with CD56+CD34-CD144- cells, CD56-CD34+CD144+ cells, and
CD56+CD34+CD144+ cells. Scale bars equal 100 μm. (B) Hearts transplanted with
CD56+CD34+CD144+ cells display a higher capillary density within the infarct when
compared to the other groups (*P<0.05, CD56+CD34+CD144+ versus CD56+CD34-CD144-
and CD56-CD34+CD144+; †P<0.05, all cell groups versus PBS).
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Figure 5. Endogenous cardiomyocyte proliferation and apoptotis
(A), (B) Proliferating cardiomyocytes within the peri-infarct region were identified by
colocalization of both ki-67 (purple nuclear stain, arrow) and cardiac troponin I (cTnI, brown
cytoplasmic stain) within the peri-infarct region (arrow). Some of the proliferating cells stained
by Ki-67 exist within the infarct zone, but do not colocalize with cTnI (arrow head). Scale bars
equal 50 μm. (C) The number of endogenous proliferating cardiomyocytes was higher in the
peri-infarct region of the heart injected with CD56+CD34+CD144+ cells compared with other
groups at both 5 days and 6 weeks after cell transplantation (*P<0.05,
CD56+CD34+CD144+ cells versus CD56+CD34-CD144- cells, CD56- CD34+CD144+ cells,
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and PBS). (D) The number of apoptotic cardiomyocytes was measured at both 5 days and 6
weeks after MI (†P< 0.05, CD56+CD34+CD144+ cells versus PBS).
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Figure 6. Growth factor expression in vitro
(A) An increase in Vegf mRNA production by CD56+CD34+CD144+ cells was observed when
cultured under hypoxia for 24 hours in comparison to control normoxic conditions. In contrast,
Hgf, b-Fgf, and Igf-I mRNA expression by human CD56+CD34+CD144+ cells either
significantly decreased or was not detectable after 24 hours of hypoxia. (B) All cell types
greatly increased their secretion of Vegf mRNA after exposure to hypoxic culture conditions
for 24 hrs when compared to control normoxia culture conditions by quantitative PCR analysis
of Vegf mRNA expression (*P<0.01, normoxia versus hypoxia). (C) These results were further
confirmed by VEGF ELISA analysis (*P<0.05, normoxia versus hypoxia).
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